002603 以岭药业
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,522,633-35.89%10,318,31312,532,84110,116,7948,782,480
减:营业总成本2,163,331-13.10%8,719,1969,666,8828,559,7117,342,875
    其中:营业成本1,224,061-11.21%4,407,8094,540,5723,680,9953,118,413
               财务费用8,4361,603.45%26,36819,92017,319(1,837)
               资产减值损失(1,559)-89.28%(35,358)(108,432)(28,630)(58,154)
公允价值变动收益12,95322.69%39,35418,7341,8535,229
投资收益3,815-187.12%25,950(7,229)(23,748)24,372
    其中:对联营企业和合营企业的投资收益(3)--(15)(3)----
营业利润391,394-73.13%1,779,8282,829,5551,569,0711,438,036
利润总额368,456-74.70%1,684,2112,780,6431,553,7181,422,472
减:所得税费用66,536-73.88%339,909422,870212,086207,541
净利润301,920-74.87%1,344,3032,357,7731,341,6321,214,931
减:非控股权益(2,008)86.37%(8,077)(4,983)(2,224)(3,807)
股东净利润303,928-74.73%1,352,3792,362,7561,343,8561,218,738

市场价值指针
每股收益 (元) *0.182-74.73%0.8101.4140.8040.730
每股派息 (元) *----0.3000.5000.3001.000
每股净资产 (元) *7.035-3.14%6.8536.5435.4287.410
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容